TriangleIn August 2023 a routine scan handed me the word lesion at dinner. The surgeon search, the molecular work-up, the vaccine built from my own tumour’s mutations. I found them because I knew how to work the system. Nobody should need to know how.
Ink
hold & drag the water
Knowledge is power
3×
higher response rate when treatment is matched to your biology
1 in 5
patients found a mistake in their own records
58%
lower risk of type 2 diabetes with intensive lifestyle change
Real studies, cited in full. See the evidence →
We specialise in cancer. Every other AI is guessing.
You
Why did you rank the targeted combination above adding radiation?
Triangle
Mostly because of the inherited TP53 finding in your germline results your sequencing, Sept 2023. Radiation spends part of a lifetime budget you can’t get back, and with that finding the risk of a second cancer later is meaningfully higher than average.
The targeted route costs you none of that budget. It also builds on the treatment you’re already having your current therapy rather than replacing it.
This is one reading of your records, not a recommendation. Your oncologist decides.
You
What would change your mind?
Triangle
Progression on the current therapy. If the disease starts moving, the calculation flips and radiation becomes worth the budget; that’s written into option four.
Illustrative exchange. Not medical advice.
What the pipeline already knows before you ask
- Ranked targeted therapies
- Matched clinical trials
- Hereditary (germline) findings
- Every alteration, tiered and evidenced
- Mutational burden and MSI
- Neoantigen candidates
- Drug metabolism, gene by gene
- Immune cell fractions
- Supplements, screened against your file
One run covers the whole patient: roughly fifty tables, re-run as your file changes. Every claim Triangle makes traces to a named source in your run. When something isn’t in your file, it says so. The full pipeline →
What it reads
Your records, your genome, and the papers. Read together.
Your whole record
Requested on your authorisation through the national networks (Carequality and TEFCA). Where a hospital is not connected, we tell you and go after it directly.
Your genome data
Sequencing read from the raw data, not from a summary. It sets a safety budget that no suggested combination may exceed.
All published science
The literature, drug labels, guidelines and every open trial, re-read against your file whenever any of it changes.
Foundational AI
The best frontier models available, pointed at your file together. When a better one arrives, your case is re-read with it.
One reading of your case
Everything on the leftabove, read together. Then you simply ask.
Why this exists · my story
The first patient was me.
Latest
What’s new, sourced.
Dated FDA notices and posted trial results from the cancer evidence library, and the newest phase 1 explainers.
Research news
- FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer
- A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
- FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer
- Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
- Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load
